Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial have?
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial has 48 citations in the OpenAlex counts ScholarIQ stores.
When was Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial published?
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial has 2024 year in the ScholarIQ index.
What is the open-access status of Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial?
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial has hybrid oa status in the ScholarIQ index.
What is the DOI of Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial?
The DOI for Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial is on the source record.
What is the PMID of Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial?
The PMID for Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial is on the source record.
What is the OpenAlex record for Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial?
The OpenAlex for Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial is on the source record.